

## **Quisinostat hydrochloride**

08/20

ALTERNATE NAMES: N-hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide

hydrochloride; JNJ-26481585

**CATALOG #:** B3066-5 5 mg B3066-25 25 mg

STRUCTURE:

MOLECULAR FORMULA:  $C_{21}H_{27}CIN_6O_2$ 

MOLECULAR WEIGHT: 430.93

**CAS NUMBER:** 1083078-98-1

APPEARANCE: Solid

PURITY: ≥98%

**SOLUBILITY**: ~20 mg/ml in DMSO

**DESCRIPTION:** Quisinostat is an inhibitor of histone deacetylase (HDAC). It shows activity toward HDAC enzymes with

highest potency for recombinant HDAC1 ( $IC_{50}=0.11$  nM) in vitro. The  $IC_{50}$  values for HDAC 2 and 3 are 0.33 nM and 4.8 nM respectively. It shows broad spectrum antiproliferative activity ( $IC_{50}$  values of

3.1-246 nM) in lung, breast, colon, prostate, brain and ovarian cancer cell lines.

**STORAGE TEMPERATURE:** -20°C. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of

exposure.

REFERENCE: Arts, J., King, P., Mariën, A., et al. JNJ-26481585, a novel "second-generation" oral histone deacetylase

inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin. Cancer. Res 15(22), 6841-6851

(2009).

**RELATED PRODUCTS:** 

4-Iodo-SAHA (Cat. No. B2800) BRD6929 (Cat. No. B2931) MPI-5a (Cat. No. B2833) 5-Nitroso-8-quinolinol (Cat. No. B2825) HNHA (Cat. No. B2821)

DISCLAIMER: FOR RESEARCH USE ONLY! Not to be used on humans.